Insulet Co. (NASDAQ:PODD) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 8.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,405 shares of the medical instruments supplier’s stock after purchasing an additional 928 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Insulet were worth $2,301,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Sunbelt Securities Inc. purchased a new stake in Insulet during the first quarter worth about $29,000. International Assets Investment Management LLC acquired a new stake in shares of Insulet during the 2nd quarter valued at approximately $32,000. UMB Bank n.a. boosted its stake in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Jones Financial Companies Lllp purchased a new stake in shares of Insulet during the 4th quarter worth approximately $40,000. Finally, CVA Family Office LLC grew its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 145 shares during the period.

Insulet Stock Performance

Shares of PODD opened at $233.87 on Friday. The company has a market capitalization of $16.40 billion, a price-to-earnings ratio of 70.87, a PEG ratio of 4.26 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $234.71. The company’s 50 day simple moving average is $199.23 and its 200 day simple moving average is $185.73.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The business had revenue of $488.50 million for the quarter, compared to analysts’ expectations of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.38 EPS. On average, sell-side analysts predict that Insulet Co. will post 3.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $234.00 price objective on shares of Insulet in a report on Tuesday, July 23rd. Barclays boosted their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. OTR Global reissued a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Redburn Atlantic began coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 target price for the company. Finally, BTIG Research lowered their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $225.29.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.